Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct-Dec;10(4):395-401.
doi: 10.4103/1658-354X.177340.

Cardiac and renal protective effects of dexmedetomidine in cardiac surgeries: A randomized controlled trial

A S Ammar  1 , K M Mahmoud  1 , Z A Kasemy  2 , M A Helwa  3
Affiliations

Cardiac and renal protective effects of dexmedetomidine in cardiac surgeries: A randomized controlled trial

A S Ammar et al. Saudi J Anaesth. 2016 Oct-Dec.

Abstract

Background: Cardiac and renal injuries are common insults after cardiac surgeries that contribute to perioperative morbidity and mortality. Dexmedetomidine has been shown to protect several organs against ischemia/reperfusion-(I/R) induced injury. We performed a randomized controlled trial to assess the effect of dexmedetomidine on cardiac and renal I/R injury in patients undergoing cardiac surgeries.

Materials and methods: Fifty patients scheduled for elective cardiac surgeries were randomized to dexmedetomidine group that received a continuous infusion of dexmedetomidine initiated 5 min before cardiopulmonary bypass (1 μg/kg over 15 min, followed by 0.5 μg/kg/h) until 6 h after surgery, whereas the control group received an equivalent volume of physiological saline. Primary outcome measures included myocardial-specific proteins (troponin-I, creatine kinase-MB), urinary-specific kidney proteins (N-acetyl-beta-D-glucosaminidase, alpha-1-microglobulin, glutathione transferase-pi, glutathione transferase alpha), serum proinflammatory cytokines (tumor necrosis factor alpha and interleukin-1 beta), norepinephrine, and cortisol levels. They were measured within 5 min of starting anesthesia (T0), at the end of surgery (T1), 12 h after surgery (T2), 24 h after surgery (T3), 36 h postoperatively (T4), and 48 h postoperatively (T5). Furthermore, creatinine clearance and serum cystatin C were measured before starting surgery as a baseline, and at days 1, 4, 7 after surgery.

Results: Dexmedetomidine reduced cardiac and renal injury as evidenced by lower concentration of myocardial-specific proteins, kidney-specific urinary proteins, and pro-inflammatory cytokines. Moreover, it caused higher creatinine clearance and lower serum cystatin C.

Conclusion: Dexmedetomidine provided cardiac and renal protection during cardiac surgery.

Keywords: Cardiac injury; cardiac surgeries; dexmedetomidine; renal injury.

PubMed Disclaimer

References

    1. Dawood MM, Gutpa DK, Southern J, Walia A, Atkinson JB, Eagle KA. Pathology of fatal perioperative myocardial infarction: Implications regarding pathophysiology and prevention. Int J Cardiol. 1996;57:37–44. - PubMed
    1. Rosner MH, Portilla D, Okusa MD. Cardiac surgery as a cause of acute kidney injury: Pathogenesis and potential therapies. J Intensive Care Med. 2008;23:3–18. - PubMed
    1. Ascione R, Lloyd CT, Underwood MJ, Lotto AA, Pitsis AA, Angelini GD. Inflammatory response after coronary revascularization with or without cardiopulmonary bypass. Ann Thorac Surg. 2000;69:1198–204. - PubMed
    1. Wallace AW. Clonidine and modification of perioperative outcome. Curr Opin Anaesthesiol. 2006;19:411–7. - PubMed
    1. Myles PS, Hunt JO, Holdgaard HO, McRae R, Buckland MR, Moloney J, et al. Clonidine and cardiac surgery: Haemodynamic and metabolic effects, myocardial ischaemia and recovery. Anaesth Intensive Care. 1999;27:137–47. - PubMed